Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

As president of the Novartis Institutes for BioMedical Research, or NIBR, Bradner leads the company's drug research and discovery. But, speaking at the World Economic Forum in Davos, Switzerland ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...